» Articles » PMID: 32899400

The Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Sep 9
PMID 32899400
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Neuromuscular disorders (NMDs) affect 1 in 3000 people worldwide. There are more than 150 different types of NMDs, where the common feature is the loss of muscle strength. These disorders are classified according to their neuroanatomical location, as motor neuron diseases, peripheral nerve diseases, neuromuscular junction diseases, and muscle diseases. Over the years, numerous studies have pointed to protein homeostasis as a crucial factor in the development of these fatal diseases. The ubiquitin-proteasome system (UPS) plays a fundamental role in maintaining protein homeostasis, being involved in protein degradation, among other cellular functions. Through a cascade of enzymatic reactions, proteins are ubiquitinated, tagged, and translocated to the proteasome to be degraded. Within the ubiquitin system, we can find three main groups of enzymes: E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin-protein ligases). Only the ubiquitinated proteins with specific chain linkages (such as K48) will be degraded by the UPS. In this review, we describe the relevance of this system in NMDs, summarizing the UPS proteins that have been involved in pathological conditions and neuromuscular disorders, such as Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth disease (CMT), or Duchenne Muscular Dystrophy (DMD), among others. A better knowledge of the processes involved in the maintenance of proteostasis may pave the way for future progress in neuromuscular disorder studies and treatments.

Citing Articles

HERC1 E3 Ubiquitin Ligase Is Necessary for Autophagy Processes and for the Maintenance and Homeostasis of Vesicles in Motor Nerve Terminals, but Not for Proteasomal Activity.

Perez-Castro M, Hernandez-Rasco F, Alonso-Bellido I, Letran-Sanchez M, Perez-Villegas E, Vitalle J Int J Mol Sci. 2025; 26(2).

PMID: 39859507 PMC: 11765733. DOI: 10.3390/ijms26020793.


Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics.

Samareh Salavatipour M, Tavakoli S, Halimi A, Tavoosi S, Baghsheikhi A, Talebi-Taheri A Front Pharmacol. 2024; 15:1356634.

PMID: 39664521 PMC: 11632177. DOI: 10.3389/fphar.2024.1356634.


Ubiquitylomics: An Emerging Approach for Profiling Protein Ubiquitylation in Skeletal Muscle.

Lord S, Johnston H, Samant R, Lai Y J Cachexia Sarcopenia Muscle. 2024; 15(6):2281-2294.

PMID: 39279720 PMC: 11634490. DOI: 10.1002/jcsm.13601.


Raw polysaccharide counteracts Alzheimer's disease in a transgenic mouse model by activating the ubiquitin-proteosome system.

Wang S, Dong K, Zhang J, Chen C, Shuai H, Yu X Nutr Res Pract. 2023; 17(6):1128-1142.

PMID: 38053824 PMC: 10694425. DOI: 10.4162/nrp.2023.17.6.1128.


Influence of Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments.

Duranti E, Villa C Int J Mol Sci. 2023; 24(11).

PMID: 37298453 PMC: 10253551. DOI: 10.3390/ijms24119503.


References
1.
Wilson S, Bhattacharyya B, Rachel R, Coppola V, Tessarollo L, Householder D . Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet. 2002; 32(3):420-5. DOI: 10.1038/ng1006. View

2.
Abera M, Xiao J, Nofziger J, Titus S, Southall N, Zheng W . ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight. 2016; 1(19):e88427. PMC: 5111506. DOI: 10.1172/jci.insight.88427. View

3.
Deng H, Chen W, Hong S, Boycott K, Gorrie G, Siddique N . Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011; 477(7363):211-5. PMC: 3169705. DOI: 10.1038/nature10353. View

4.
Blasco H, Mavel S, Corcia P, Gordon P . The glutamate hypothesis in ALS: pathophysiology and drug development. Curr Med Chem. 2014; 21(31):3551-75. DOI: 10.2174/0929867321666140916120118. View

5.
Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfi S, Pistorio A . Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol. 2010; 176(4):1863-77. PMC: 2843476. DOI: 10.2353/ajpath.2010.090468. View